"The depth of experience of our new board members will provide significant contributions to our worldwide efforts to transform the cardiovascular translational research process." Dr. Nabil Dib, ISCTR President
Gilbert, Arizona (PRWEB) November 14, 2014
The International Society for Cardiovascular Translational Research, ‘ISCTR’ announced today that the society’s Governing Board has grown with the additions of Stanton J. Rowe, Edwards Lifesciences chief scientific officer and Dr. Charles Simonton, divisional vice president, Medical Affairs, chief medical officer, Abbott Vascular. Mr. Rowe and Dr. Simonton are both medical industry leaders and medical device development experts.
Dr. Nabil Dib, ISCTR President stated, “We are delighted to expand our Governing Board with industry leaders like Stanton Rowe and Dr. Charles Simonton. The depth of experience of our new board members will provide significant contributions to our worldwide efforts to transform the cardiovascular translational research process. As medical industry leaders, they offer unique perspectives on translational research. We are anxious to have their input on current and planned ISCTR initiatives.” Dr. Dib continued, “ISCTR remains at the forefront of transformative structural development focused on cardiovascular translational research. Our new Governing Board members embolden our efforts to expedite advancements in medical innovations that lead to improved patient care and outcomes, while reducing costs.”
When notified of the unanimous vote confirming Mr. Rowe and Dr. Simonton to the ISCTR Governing Board, Stanton Rowe offered “Thank you very much for the honor of joining the very impressive Governing Board of ISCTR. I hope that the lessons that I learn each year in the practice of translational research from the Industry side can benefit the collective knowledge of this board.” Dr. Simonton added, “I am honored to join the board of directors for ISCTR given the society’s focus on bringing together key stakeholders across healthcare sectors to accelerate the pace of innovation. I look forward to sharing my perspective as a scientific leader in the medical device industry and as a former practicing interventional cardiologist.”